Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.

Abstract

Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. Early detection of lung cancer is an important opportunity for decreasing mortality. Data support using low-dose computed tomography (LDCT) of the chest to screen select patients who are at high risk for lung cancer. Lung screening is covered under the Affordable Care Act for individuals with high-risk factors. The Centers for Medicare & Medicaid Services (CMS) covers annual screening LDCT for appropriate Medicare beneficiaries at high risk for lung cancer if they also receive counseling and participate in shared decision-making before screening. The complete version of the NCCN Guidelines for Lung Cancer Screening provides recommendations for initial and subsequent LDCT screening and provides more detail about LDCT screening. This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for LDCT of the chest and on evaluating initial screening findings.

Publication types

  • Meta-Analysis
  • Practice Guideline
  • Review

MeSH terms

  • Clinical Decision-Making
  • Cost-Benefit Analysis
  • Early Detection of Cancer / methods
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / epidemiology
  • Mass Screening* / methods
  • Multimodal Imaging / methods
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Tomography, X-Ray Computed* / methods
  • Tumor Burden
  • United States